FL4OWS: Fluoride Delivery to Prevent White Spots During Orthodontic Treatment

Sponsor
Liverpool University Hospitals NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05005689
Collaborator
(none)
130
2
36

Study Details

Study Description

Brief Summary

The aim of this 2-armed, parallel, randomised, controlled trial is to assess the effect of different ways of applying fluoride to teeth on the formation of white spots (enamel demineralisation), during orthodontic treatment with fixed metal braces, in children and adolescents.

Condition or Disease Intervention/Treatment Phase
  • Drug: Fluoride mouthwash (0.05%; 225ppm).
  • Drug: Tooth Mousse Plus
Phase 4

Detailed Description

One of the most common side-effects and risks of orthodontic treatment with fixed (metal) braces is damage to the outer surface (enamel) of the teeth. This damage can take the form of white or brown spots on the teeth (white spot lesions; WSLs) or if severe, holes in the teeth that need a filling.

The aims of this study are to find out the best way of preventing damage to the teeth of children and adolescents who are under going orthodontic treatment with fixed (metal) braces.

The participants will be 130 children, aged 11-16 years old, inclusive. The participants will be split into two groups using a process called randomisation. The treatments will be standard fluoride toothpaste (Colgate) and either:

  1. Fluoride mouth wash (Fluorigard) or

  2. Tooth Mousse Plus

The participants' teeth will be checked at every visit and the brace adjusted. Photographs of the participants' teeth will be taken very 3 months to see if any of the teeth have been damaged. The participants will be asked about the impact of their teeth on their life. Participants and parents will be asked about the impact of any white spots that form on the participants' teeth during the treatment with fixed (metal) braces.

The study will follow the participants through the whole length of treatment which will take about 2 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Randomised, Controlled Trial to Assess the Effect of Different Modes of Fluoride Delivery on Enamel Demineralisation, During Orthodontic Treatment With Fixed Appliances
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Sep 30, 2025
Anticipated Study Completion Date :
Sep 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mouthwash

Fluoride mouthwash (0.05%; 225ppm) 10ml for 1 minute daily

Drug: Fluoride mouthwash (0.05%; 225ppm).
Mouthwash
Other Names:
  • Fluorigard
  • Experimental: Tooth Mousse

    Tooth Mousse Plus (Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w; 900 ppm). Tooth creme; 2ml smear daily

    Drug: Tooth Mousse Plus
    Tooth Mousse
    Other Names:
  • Recaldent™ CPP-ACP [casein phosphopeptide (CPP)-amorphous calcium phosphate (ACP)] and Sodium Fluoride 0.2% w/w (900 ppm).
  • Outcome Measures

    Primary Outcome Measures

    1. New white spot lesions (WSLs) [Through to study completion, an average of 2 years]

      The incidence of new demineralisation (WSLs), developing on the anterior teeth during fixed orthodontic treatment assessed from white light and quantitative light-induced fluorescence (QLF) images, will be measured. Numerical scale 0 - unlikely to be more than 100. Higher score is worse.

    Secondary Outcome Measures

    1. Size of white spot lesion (WSL) [Through to study completion, an average of 2 years]

      The degree (∆F) of enamel demineralisation on the surfaces of the anterior teeth measure from quantitative light-induced fluorescence (QLF) images. Measured as a percentage (%) compared to baseline i.e. loss of mineral. Scale ∆F 0% to -100%; Higher score is worse.

    2. Extent of white spot lesion (WSL) [Through to study completion, an average of 2 years]

      The extent (∆Q) of enamel demineralisation on the surfaces of the anterior teeth. measure from quantitative light-induced fluorescence (QLF) images. Measured as a percentage per millimetre squared (%mm-2) compared to baseline i.e. loss of mineral. Scale ∆Q 0% to -100%mm-2. Higher score is worse.

    3. Participants' perception of WSL [Through to study completion, an average of 2 years]

      Participants' perception of the WSLs. Measured on 100mm visual analogue scale (VAS). Scale 0 to 100. Higher score is worse.

    4. Parents' perception of WSL [Through to study completion, an average of 2 years]

      Parents' perception of the WSLs. Measured on 100mm visual analogue scale (VAS). Scale 0 to 100. Higher score is worse.

    5. MIQ Score [Through to study completion, an average of 2 years]

      Malocclusion Impact Questionnaire (MIQ) score. Measured using a 17-item questionnaire. Total score will be used where minimum score is 0 and maximum score is 34; higher score indicates poorer oral health related quality of life (OHRQoL).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    11 Years to 16 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Planned to receive orthodontic treatment with upper and lower fixed orthodontic appliances (braces) either alone or following a period of functional appliance treatment.

    • 11-16 years of age inclusive at the start of the fixed orthodontic appliance treatment.

    • All genders.

    • Fit and well with no chronic disease necessitating regular hospital follow-up at hospital.

    • Willing to participate

    Exclusion Criteria:
    • Significant disabilities that may affect manual dexterity;

    • Any medical complication that would contraindicate the use of the fluoride treatments or milk products;

    • Previous orthodontic treatment except Phase I functional appliance treatment;

    • From areas that have fluoridated water supply*;

    • Full coronal coverage restorations;

    • More than 2 missing anterior teeth;

    • Showing signs of systemic illness e.g. fever, cough, loss of taste/smell;

    • Any abnormality of face, lips e.g. cleft lip and/or palate or craniofacial abnormality or soft tissues of the mouth e.g. aphthous ulcers or connective tissue disorder.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Liverpool University Hospitals NHS Foundation Trust

    Investigators

    • Study Chair: Heather Rogers, Liverpool University Hospitals NHS Foundation Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Liverpool University Hospitals NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT05005689
    Other Study ID Numbers:
    • 5604
    First Posted:
    Aug 13, 2021
    Last Update Posted:
    Jun 3, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Liverpool University Hospitals NHS Foundation Trust
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 3, 2022